The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Definition and clinical significance of the MGUS-like phenotype in patients with monoclonal gammopathies
Featured:
Bruno PaivaThe Multiple Myeloma Hub was pleased to speak with steering committee member, Bruno Paiva, University of Navarra, Pamplona, ES. We asked, What is the definition and clinical significance of the monoclonal gammopathy of undetermined significance (MGUS)–like phenotype in patients with monoclonal gammopathies?
Definition and clinical significance of the MGUS-like phenotype in monoclonal gammopathies
In this presentation, Paiva summarizes a recent publication1 and discusses the current lack of standardized methods to identify the subgroup of patients with multiple myeloma and light-chain (AL) amyloidosis who have MGUS-like phenotype. He goes on to outline the flow cytometry-based tool that was developed to address this issue and provides the key data it produced with a focus on progression-free and overall survival outcomes. Paiva concludes with the clinical applications of this tool and discusses how these data can help subdivide groups of patients to inform a more individualized treatment approach.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content